bioAffinity Technologies (NASDAQ:BIAF) Rating Lowered to “Sell” at Wall Street Zen

bioAffinity Technologies (NASDAQ:BIAF) was downgraded by research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a note issued to investors on Sunday.

Separately, Weiss Ratings downgraded bioAffinity Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, April 22nd. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, bioAffinity Technologies presently has an average rating of “Sell”.

bioAffinity Technologies Price Performance

NASDAQ BIAF opened at $0.83 on Friday. bioAffinity Technologies has a 12 month low of $0.69 and a 12 month high of $13.50. The stock has a market cap of $3.93 million, a price-to-earnings ratio of -0.07 and a beta of -1.11. The company’s 50 day moving average is $1.56 and its two-hundred day moving average is $1.75. The company has a current ratio of 1.36, a quick ratio of 1.34 and a debt-to-equity ratio of 0.15.

bioAffinity Technologies (NASDAQ:BIAF) last posted its quarterly earnings results on Friday, May 8th. The company reported ($0.81) EPS for the quarter, beating analysts’ consensus estimates of ($2.40) by $1.59. bioAffinity Technologies had a negative return on equity of 285.75% and a negative net margin of 280.53%.The business had revenue of $1.35 million for the quarter, compared to analysts’ expectations of $1.48 million.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of BIAF. Geode Capital Management LLC bought a new stake in bioAffinity Technologies in the fourth quarter worth $36,000. Scientech Research LLC purchased a new stake in bioAffinity Technologies during the third quarter valued at $49,000. J. Safra Sarasin Holding AG bought a new position in bioAffinity Technologies during the first quarter valued at $164,000. Finally, Sabby Management LLC bought a new position in bioAffinity Technologies during the third quarter valued at $719,000. 1.64% of the stock is currently owned by institutional investors.

bioAffinity Technologies Company Profile

bioAffinity Technologies, Inc (NASDAQ: BIAF) is a U.S.-based biotechnology company specializing in the development and commercialization of advanced in vitro diagnostic platforms for oncology. Leveraging proprietary bioaffinity and nanotechnology approaches, bioAffinity’s platforms are designed to isolate and analyze cancer-specific biomarkers from blood, tissue, and other biological samples with high sensitivity and specificity. The company’s core technologies aim to enable earlier detection of solid tumors, improved disease monitoring, and more personalized treatment strategies.

The company’s primary product pipeline includes assays targeting breast cancer and other solid tumor indications.